Back to search

Aristotle University Of Thessaloniki (AUTH)

Σύγκριση αποτελεσματικότητας και ασφάλειας των φαρμακευτικών παρεμβάσεων για την ελκώδη κολίτιδα: μετα-ανάλυση πολλαπλών παρεμβάσεων

Abstract

dc:description

AIM: Aim of the present thesis was to assess the efficacy, the safety, and the impact on the quality of life of pharmaceutical interventions for mild to moderate and moderate to severe ulcerative colitis. METHODS: We assessed the comparative efficacy and safety of pharmaceutical interventions using multiple-treatment meta-analysis. We searched Medline, Embase, CENTRAL and grey literature sources. We included all available interventions for both mild to moderate and moderate to severe ulcerative colitis. We analysed data separately for induction of remission and maintenance of remission. For each available comparison explored by at least two trials, we performed a pairwise meta-analysis with a random-effects model. We performed random-effects network meta-analysis, using the frequentist approach. Dichotomous outcomes were analysed by calculating pooled odds ratio (OR) and continuous outcomes were analysed by calculating the mean differences (MD) and 95% confidence intervals (CI). We obtained hierarchy of the competing interventions using the surface under the cumulative ranking curve (SUCRA). We evaluated the quality of evidence contributing to each network estimate by using CINeMA (Confidence in Network Meta-Analysis). RESULTS: We included 48 clinical trials comparing 7 monotherapies [mesalazine (≥ 2.4gr/day, < 2,4gr/day), olsalazine, balsalazide, sulfasalazine, beclomethasone, budesonide ΜΜΧ and probiotics] and 2 combinations treatments (combined oral and rectal mesalazine, combined beclomethasone and mesalazine) as induction therapy in patients with active, left-sided, and extensive, mild to moderate ulcerative colitis. The 2 combination treatments were the most effective treatment strategy, with adequate safety profile. However, data on combined beclomethasone and mesalazine were derived from only one study. High dose mesalazine (≥ 2.4gr/day) was superior to lower dose. Balsalazide was the safest intervention. Olsalazine and budesonide MMX were equally effective to mesalazine, but they ranked lowest for safety. Sulfasalazine was not superior to placebo for efficacy and it was inferior compared to other treatments in safety. Finally, probiotics were not effective in induction of remission. The efficacy in maintenance of remission was evaluated in 30 clinical trials, comparing 5 monotherapies [mesalazine (≥ 2gr/day, < 2gr/day), olsalazine, balsalazide, sulfasalazine and probiotics] and 2 combination treatments (combined oral and rectal mesalazine, combined probiotics and mesalazine). Combined oral and rectal mesalazine was also the most effective treatment strategy since it was superior to all other available interventions. All treatments were superior to placebo, without any significant differences among them. No differences were detected in safety outcomes, but sulfasalazine and olsalazine were ranked lowest on SUCRA analysis. High dose mesalazine (> 2gr/ημέρα) had numerically lower rates of relapse compared to low dose mesalazine. Probiotics were effective especially when combined with mesalazine. For moderate to severe ulcerative colitis, infliximab, adalimumab, golimumab, vedolizumab and tofacitinib were evaluated as induction therapy in 16 placebo-controlled trials and as maintenance therapy in 11 placebo-controlled trials. In patients without prior exposure to anti-TNF therapy, all interventions were effective in both induction and maintenance of clinical remission. There were no differences among treatments except for infliximab which was superior to adalimumab and golimumab in induction of mucosal healing. On SUCRA analysis, infliximab and vedolizumab were ranked highest for induction of remission. However, these results should be interpreted with caution since there was significant overlap in confidence intervals. In patients with prior exposure to anti-TNF, only evidence for adalimumab, vedolizumab and tofacitinib were available. Only vedolizumab and tofacitinib (5mg και 10mg) were effective. All available interventions improved quality of life as induction therapy compared to placebo. Only infliximab and vedolizumab achieved clinically significant improvement. Evidence on quality of life during maintenance phase were scarce. Evidence with very low confidence indicate that adalimumab, vedolizumab and tofacitinib improved quality of life. All medical interventions were safe and vedolizumab had the lowest rates in most safety outcomes. CONCLUSION: In patients with left-sided or extensive, mild to moderate ulcerative colitis, combined oral and rectal mesalazine is the first treatment choice for induction and maintenance of remission. For patients who cannot tolerate or comply with rectal mesalazine, combined beclomethasone and oral mesalazine could be an alternative option, although more evidence are needed. Mesalazine, olsalazine and balsalazide and budesonide MMX are equally effective, but olsalazine seems less tolerated from patients. High dose mesalazine has better remission rates compared to lower doses. Evidence on probiotics are limited and heterogenous. Probiotics do not seem to contribute to induction of remission but they may reduce the rates of relapse when combined with mesalazine. In patients with moderate to severe ulcerative colitis and without prior exposure to anti-TNF therapy, all interventions are effective. Infliximab and vedolizumab are ranked highest for induction of remission. In patients with prior exposure to anti-TNF therapy, only vedolizumab and tofacitinib are effective.

Degree

thesis:*
Grantor dc:publisher
Aristotle University Of Thessaloniki (AUTH)
Year dc:date
2021

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Paschos, Paschalis
  • Πάσχος, Πασχάλης

Subjects

dc:subject × 10

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/48997

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Paschos, Paschalis; Πάσχος, Πασχάλης. Σύγκριση αποτελεσματικότητας και ασφάλειας των φαρμακευτικών παρεμβάσεων για την ελκώδη κολίτιδα: μετα-ανάλυση πολλαπλών παρεμβάσεων. Aristotle University Of Thessaloniki (AUTH), 2021. http://hdl.handle.net/10442/hedi/48997